Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Earnings Data
Report Date
Feb 04, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.26Last Year’s EPS
0.23Same Quarter Last Year
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
GSK's Q3 2025 earnings call highlighted strong financial performance, driven by growth in Specialty Medicines and the HIV portfolio, alongside successful R&D progress. However, challenges in the U.S. vaccines market and delays in clinical trial supply for HIV treatment were noted. The overall sentiment is positive, with a focus on continued growth and innovation.Company Guidance
Strong Financial Performance and Upgraded Guidance
GSK reported an 8% increase in total sales for Q3 2025, with core operating profit up 11% and core earnings per share up 14%. The company raised its full-year sales expectations from 3%-5% to 6%-7% and upgraded guidance ranges for operating profit to 9%-11% and EPS to 10%-12%.
Specialty Medicines Drive Growth
Specialty Medicines sales were up 16%, with significant contributions from RI&I, oncology, and HIV. Key products like Nucala and Benlysta showed strong demand, with sales increases of 14% and 17% respectively.
Successful R&D and Pipeline Expansion
GSK secured four FDA approvals so far in the year, with the potential for a fifth before year-end. The company is investing $30 billion in R&D and advanced manufacturing in the U.S. over the next 5 years.
HIV Portfolio Performance
The HIV portfolio grew by 12%, driven by strong demand for long-acting injectables like Cabenuva, which increased by 48%. The company upgraded its 2025 guidance for HIV growth from mid- to high single digits to around 10%.
GB:GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | 1399.37p | 1449.70p | +3.60% |
Feb 05, 2025 | 1333.55p | 1435.01p | +7.61% |
Oct 30, 2024 | 1387.19p | 1344.67p | -3.07% |
Jul 31, 2024 | 1460.32p | 1431.45p | -1.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GlaxoSmithKline (GB:GSK) report earnings?
GlaxoSmithKline (GB:GSK) is schdueled to report earning on Feb 04, 2026, Before Open (Confirmed).
What is GlaxoSmithKline (GB:GSK) earnings time?
GlaxoSmithKline (GB:GSK) earnings time is at Feb 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of GlaxoSmithKline stock?
The P/E ratio of GlaxoSmithKline is N/A.
What is GB:GSK EPS forecast?
GB:GSK EPS forecast for the fiscal quarter 2025 (Q4) is 0.26.